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Summary:  In START, immediate cART initiation reduced risk of infection-related cancer by 
74% and infection-unrelated cancer by 51%. Adjustment for potential mediators, such as HIV 
RNA, appeared to attenuate HRs of immediate/deferred cART for infection-unrelated cancer 
more than infection-related cancer. cART benefit in reducing cancer risk may be mediated 
by mechanisms beyond HIV suppression. 
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Abstract  
Background: In the START study, immediate combination antiretroviral therapy (cART) 
reduced cancer risk by 64%. We hypothesized that risk reduction was higher for infection-
related cancer and determined by differences in CD4 counts and HIV RNA between the 
study arms.  
Methods: Incident malignancies in START were categorized into infection-related and 
infection-unrelated cancer. We used Cox models to assess factors associated with both 
cancer categories. We used sequential adjustment for baseline covariates, cancer risk 
factors and HIV-specific variables to investigate potential mediators of cancer risk reduction 
with immediate cART. 
Results: There were 14 cancers among persons randomized to immediate cART (6 
infection-related and 8 infection-unrelated) and 39 cancers in the deferred arm (23 infection-
related and 16 infection-unrelated) (Hazard Ratios; 95% CI; of immediate vs deferred cART 
initiation were 0.26; 0.11-0.64; for infection-related and 0.49; 0.21-1.15; for infection-
unrelated cancer). Independent predictors of infection-related cancer were older age, higher 
BMI, low-middle income region, HIV RNA and baseline CD8 count. Older age and baseline 
CD8 count were independent predictors of infection-unrelated cancer. Adjustment for latest 
HIV RNA level had little impact on the protective effect of immediate cART on infection-
related cancer. Adjustment for latest HIV RNA level, but not for CD4 count or cancer risk 
factors, attenuated the effect of immediate cART on infection-unrelated cancer. 
Conclusions: Immediate cART initiation significantly reduces risk of cancer. Though limited 
by small sample size, this benefit doesn’t appear to be solely attributable to HIV RNA 
suppression and may be also mediated by other mechanisms.  
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Introduction 
    HIV+ persons have an increased risk of cancer when compared to the general population. 
Many reasons have been postulated for this including immunodeficiency [1-4], higher 
prevalence of traditional cancer risk factors [5] and co-infection by oncogenic viruses, direct 
pro-oncogenic effects of HIV [6], long term combination antiretroviral therapy (cART) toxicity 
[7,8] and activated inflammation and coagulation [9,10]. Because of this inherent increased 
risk and given the fact that HIV+ persons are now living much longer [11], cancer has 
emerged as a major cause of morbidity and death in the cART era [12].  
    HIV infection [13] and other immunodeficiency disorders [14,15] are associated with a 
higher risk of infection-related cancer. According to recent estimates, up to 40% of cancer 
cases among HIV+ persons in the USA are infection-related [16]; an attributable fraction ten 
times as high as in the general population. HIV+ persons also have an increased risk of 
infection-unrelated cancer [17]. Reduced control of oncogenic viruses and impaired immune 
surveillance of malignant cells may facilitate carcinogenesis during HIV infection [18]. 
    The Strategic Timing of Antiretroviral Treatment (START) trial randomized HIV+ adults 
with a CD4 count over 500 cells/mm3 to immediate cART initiation or cART deferral until 
CD4 counts dropped below 350 cells/mm3. Immediate cART reduced of risk of cancer by 
64% [19]. This was a surprising finding because START recruited young participants with 
early HIV infection and a median CD4 count of 651 cell/mm3 at study entry. Here, we set out 
to determine factors associated with cancer development among START participants and 
assess mediators of the benefit of immediate cART in reducing cancer risk. Our a priori 
hypothesis was that the reduction in cancer risk was higher for infection-related versus 
infection-unrelated cancer and mainly determined by differences in CD4 counts and HIV 
RNA levels between the study arms.  
 
Methods  
    The methods and results of the START study have been described in detail elsewhere 
[19]. In short, START randomised 4,685 HIV+ participants from 35 countries to start cART 
immediately or to defer cART initiation until CD4 counts dropped below 350 cells/mm3 or 
AIDS-defining illnesses developed. After a mean follow up of 3.0 years, the START data and 
safety monitoring board determined that pre-defined stopping rules were met for the primary 
endpoint of a composite of serious AIDS-related and non-AIDS-related events and 
recommended that all participants be offered cART. In the immediate cART arm, average 
CD4 counts during follow up were 194 cells/mm3 higher than in the deferred cART arm [19]. 
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START was conducted in compliance with the Declaration of Helsinki Guidelines, was 
registered on clinical trial databases (ClinicalTrials.gov number: NCT00867048) and 
reviewed by an independent data and safety monitoring board. The institutional review board 
at each study site approved the original study protocol, and written informed consent was 
obtained from all participants. 
    An endpoint review committee independently validated all reported cancer events. All 
cancer cases were considered definitive events with the exception of one case of leukemia 
that was classified as probable. We categorized incident malignancies in START into 
infection-related and infection-unrelated cancer after individual review of case report forms 
and source documentation. Infection-related cancer was defined as cancer driven by the 
following infectious agents: human herpesvirus 8 (HHV-8) (Kaposi sarcoma), Epstein-Barr 
virus (EBV) (non-Hodgkin lymphoma, Hodgkin lymphoma), human papillomavirus (anal 
cancer, cervical cancer) [20]. All other malignancies were classified as infection-unrelated 
cancer, including one liver cancer in a participant with no evidence of hepatitis B or C co-
infection and one gastric cancer in a participant without previous history of Helicobacter 
pylori infection. No cases of pharyngeal lymphoepithelioma or Merkel-cell carcinoma were 
observed.    
 
Statistical analyses 
    Participants were followed from study entry until first cancer event, death, loss to follow-
up, or May 25th 2015 (date of database closure), whichever occurred first. We calculated 
annual rates of any type cancer in each study arm and examined the trends within study 
group using unadjusted Poisson regression models. Kaplan-Meier (KM) curves giving the 
cumulative percentage of participants with infection-related and infection-unrelated cancer 
were constructed for each study arm. We tested for the difference in treatment group hazard 
ratios (HRs) for infection-related cancer versus infection-unrelated cancer by fitting a Cox 
regression model that simultaneously estimated both treatment group HRs and stratified by 
type of event. 
    Multivariable Cox models identified factors independently associated with risk of infection-
related and infection-unrelated cancer. The statistical power was insufficient to investigate 
individual cancer types. Epidemiologically important and biologically plausible baseline 
variables were investigated: demographics (age, sex, race and region), medical history 
(current smoking, alcohol abuse, body mass index, hepatitis B or C co-infection and prior 
cancer) and HIV-specific variables (CD4 count, CD8 count, CD4:CD8 ratio and HIV RNA 
level). Variables associated with cancer risk in univariate analyses were subsequently 
mutually adjusted for.  
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    To explore potential mediators of the reduced cancer risk from immediate cART, Cox 
proportional hazards models with an indicator for treatment group were adjusted sequentially 
for demographics, traditional cancer risk factors, and baseline and time-updated  HIV-
specific variables. The following models were used: A) univariable with a single treatment 
group indicator; B) adjusted for baseline covariates: age, gender, race, geographical region, 
smoking, BMI, hepatitis B/C, CD4 count and log10 HIV RNA; C) adjusted for latest CD4 
count, modelled as a continuous variable; D) adjusted for latest HIV RNA, modelled as ≤200 
copies/mL vs HIV RNA >200 copies/mL; E) adjusted for latest CD4 count and latest HIV 
RNA (≤200 vs >200 copies/mL); F) as in B) with further adjustment for latest CD4 count and 
latest HIV RNA (≤200 vs >200 copies/mL); G) adjusted for latest log10 HIV RNA and H) 
adjusted for latest CD4:CD8 ratio 
 
Secondary analyses 
     We repeated analyses excluding premalignant or low-grade lesions not requiring 
chemotherapy (one participant had micro-invasive squamous cell carcinoma and 
anal intraepithelial neoplasia grade III which was classified as anal cancer in the main 
analyses), localised skin squamous carcinoma (n=2) and Kaposi sarcoma restricted to the 
skin without internal organ involvement (n=7). This was done because these lesions have 
low morbidity or can be reversed or cured by cART initiation alone [21,22].  
Results 
    There were 14 malignancies among persons randomized to the immediate cART arm (6 
infection-related and 8 infection-unrelated) and 39 malignancies in the deferred arm (23 
infection-related and 16 infection-unrelated). Types of infection-related and infection-
unrelated cancer stratified by treatment group are listed in Table 1. Baseline characteristics 
of participants with no cancer and with infection-related and infection-unrelated cancer are 
shown in Table 2.  
    On the one hand, in the immediate cART arm, annual incidences of any type cancer 
remained stable throughout the entirety of follow up (p value for trend= 0.790). On the other 
hand, in the deferred cART arm, annual incidences of any type cancer increased 
significantly during follow up (p= 0.026) (Figure 1). HR; 95% CI; of immediate versus 
deferred cART initiation was 0.28; 0.13-0.58; p<0.001; for any type cancer after the 
exclusion of cancer events occurring in the first year of follow up. Among participants with 
any type cancer, the latest median (interquartile range [IQR]) CD4 count at time of cancer 
diagnosis was 861 (680-1082) cells/mm3 in the immediate cART arm and 586 (452-664) 
cells/mm3 in the deferred cART arm.  In the deferred arm, 13 malignancies (8 infection-
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related and 5 infection-unrelated) were diagnosed after cART initiation.  The median (IQR) 
time from cART initiation to cancer diagnosis was 134 (39-1,225) days in the deferred arm.     
    Immediate cART significantly reduced the risk of infection-related cancer by 74% (HR; 
95% confidence interval [CI]; of immediate vs deferred cART initiation 0.26; 0.11-0.64; 
p=0.003). KM curves overlapped during the first year; afterwards, the lower risk of infection-
related cancer in the immediate cART arm became evident and remained so for the rest of 
follow up (Figure 2). The lower risk of infection-related cancer in the immediate cART arm 
was driven mainly by a reduction of cases of Kaposi sarcoma and non-Hodgkin lymphoma 
(Table 1).   
    Immediate cART lowered the risk of infection-unrelated cancer by 51% (95% CI 21%-
115%; p=0.103). This risk reduction did not reach statistical significance (Figure 3). This 
seemed to suggest that immediate cART reduced the risk for infection-related cancer more 
than infection-unrelated cancer. However, when we tested the difference in HRs for 
infection-related versus infection-unrelated cancer we found no statistical significance (p-
value for comparing the treatment group HRs for infection-related vs infection- unrelated 
cancers: 0.27).     
     In adjusted analyses with both treatment groups combined, independent baseline 
predictors of infection-related cancer were older age (1.42; 0.99-2.02 per 10y older), higher 
BMI (1.47; 1.05-2.05 per 5Kg/m2), low-middle income region (3.40, 1.44-8.02 versus high 
income region), baseline HIV RNA (2.01; 1.17-3.47 per 1log10 higher) and baseline CD8 
count (1.13; 1.03-1.24 per 200 cells/mm3 higher) (Figure 4). Older age (2.54; 1.72-3.73 per 
10y older) and baseline CD8 count (1.12; 1.01-1.25 per 200 cells/mm3 higher) were the only 
independent predictors of infection-unrelated cancer (Figure 4).  
    Figure 5 shows the impact of sequential adjustment for baseline and time-updated 
variables on the protective effect of immediate cART initiation on any type cancer risk. 
Adjustment for demographics, traditional cancer risk factors and CD4 counts (Models B-C) 
had no appreciable effect on the estimates of overall effect. Adjustment for latest HIV RNA 
level (Models D-G) and CD4:CD8 ratio (Model H) attenuated the protective effect of 
immediate cART on any type cancer by partially attenuating the overall effect and enlarging 
95% CIs. The effect of immediate cART was no longer significant in models D-H suggesting 
that the effect of cART is partially mediated through effects on these parameters. 
     As for infection-related cancer, results were broadly consistent across the models with 
HRs varying from 0.26 to 0.48 (Figure 5). Adjustment for latest HIV RNA levels (Models D-
G), in particular when modelled as continuous variable (Model G), and CD4:CD8 ratio 
(Model H) partially attenuated the effect of immediate cART on the risk of infection-related 
cancer.   
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    With respect to infection-unrelated cancer, the measurable effect of sequential 
adjustments on the protective effect of immediate cART appears to be stronger (Models D-F) 
For instance, HRs (immediate cART/ deferred cART) for infection-unrelated cancer 
increased from 0.49 (Model A) to 1.07 (Model E) after adjustment. However, the overall 
number of cancer events was too small and no definitive statement can be made about the 
degree of attenuation of the protective effect of immediate cART after adjustment.         
    Secondary analyses excluding pre-malignant lesions and localized cancer did not change 
these conclusions.  
 
Discussion 
    In a large randomised HIV trial from across the globe, we report that immediate cART 
initiation significantly reduced the risk of infection-related cancer. This effect was mainly 
driven by a reduction in cases of Kaposi sarcoma and non-Hodgkin lymphoma. These were 
unexpected results because START enrolled participants with early HIV infection and follow 
up time was shorter than initially planned. Contrary to what we first  hypothesised, 
adjustment for CD4 counts had no impact on the protective effect of immediate cART on any 
type and infection-related cancer and adjustment for HIV RNA levels only partially 
attenuated this association. Taken together, these findings suggest that the benefit of 
immediate cART in reducing cancer goes beyond HIV RNA suppression and immune status 
as assessed by CD4 counts and seems likely to be also mediated by other mechanisms 
impacting co-infections with pro-oncogenic virus and immune surveillance.  
    With the changing epidemiology of cancer during HIV infection, the traditional 
classification into AIDS-defining and non-AIDS-defining cancer, implemented in the early 90s 
for surveillance purposes [23], became outdated [18]. The classification of cancer into 
infection-related and infection-unrelated seems to us more appropriate because it considers 
a wider range of cancer types whose incidence is increased during immunosuppression and 
establishes a framework to better understand the interplay between viral co-infections, HIV 
and carcinogenesis. However, as pointed out by others [24], this classification is not perfect 
because, even when considering a given cancer type such as non-Hodgkin lymphoma, an 
infectious origin can only be ascertained in a subset of cases. This classification can only be 
definitive after a thorough search for pathogens in tissue samples using in situ hybridization. 
    Consistent with previous reports [25], we observed that infection-related and infection-
unrelated cancer may have different predictors. Low-middle income region and baseline HIV 
RNA were associated with risk of infection-related cancer, which reflects a higher burden of 
these malignancies in resource constrained settings and suggests a stronger link between 
HIV RNA viremia and malignancies caused by pro-oncogenic viruses [26,27]. Older age and 
higher CD8 cells were independent predictors of both infection-related and infection-
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unrelated cancer. Indeed, a recent report linked elevations in CD8 cells after cART initiation 
to viral co-infections and non-AIDS death [28].     
    Because cART improves immune function, lowers HIV viral load, and reduces 
inflammation [29], earlier cART initiation had previously been proposed as an approach to 
reduce cancer risk among HIV+ persons [2-4]. Furthermore, cohort studies had long 
identified a relationship between immunodeficiency and uncontrolled HIV RNA replication 
with risk of non-Hodgkin lymphoma and Kaposi sarcoma [1,2]. However, this benefit was 
estimated in previous studies when cART was initiated at much lower CD4 counts. In 
START, cART was initiated at higher CD4 counts before the development of overt 
immunosuppression; still, the benefit of immediate cART in reducing cancer risk seems to be 
larger than previously estimated by observational studies [30].     
    The benefit of immediate cART initiation in reducing infection-related cancer was 
determined by a marked decrease in cases of non-Hodgkin lymphoma and Kaposi sarcoma. 
The mechanisms by which EBV and HHV-8 may foster carcinogenesis are complex and not 
fully understood [31,32]. In both cases, common viral infections cause rare malignancies; 
this highlights the potential contribution of multifactorial non-viral factors to the development 
of infection-related cancer.  
    EBV establishes long-term latent infections in B cells and may act just as an initial 
promoter of cellular transformation from which subsequent progression to cancer is 
independent [31,32]. The dominant EBV latency patterns observed in non-Hodgkin 
lymphoma tissue differs between pre- [33] and post-cART studies [34]. It was hypothesised 
that cART increases immune surveillance of proteins expressed by cells latently infected by 
EBV resulting in a shift to a less oncogenic latency pattern [34].  
    As for HHV-8 infection, immunosuppression is clearly a major contributor to progression to 
Kaposi sarcoma, whereas recent evidence points out the importance of complex immune 
modulation mechanisms [35]. Questions remain as to how cART interferes with such 
mechanisms. In a randomised trial involving participants with tuberculous pericarditis 
predominantly co-infected with HIV, glucocorticoids and immunotherapy with non-pathogenic 
mycobacteria acted synergistically to increase risk of Kaposi sarcoma [35].  
    CD8 T-cell dysfunction in the setting of untreated HIV infection may also be an important 
contributor. Depleted response from EBV- and HHV-8-specific CD8 cytotoxic cells may 
facilitate carcinogenesis among immunocompromised hosts [36]. The extent to which the 
normalization of the CD4:CD8 ratio following cART initiation reflects a recovery of CD8 cell 
response is unclear [37], but this may explain why adjustment by CD4:CD8 partially 
attenuated the benefit of immediate cART in reducing cancer risk.   
   Our study had important limitations. First, this is a post hoc analysis of a trial whose 
sample size was not calculated to assess reductions in cancer risk. Second, START had a 
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follow up shorter than initially planned. As a result, we cannot exclude the possibility that 
immediate cART could have significantly reduced the risk of infection-unrelated cancer if a 
longer follow up with larger number of events had accrued. It is unclear whether the non-
significant reduction in infection-unrelated cancer just reflected limited power to detect 
differences or was instead a true observation. The first possibility is favoured by the lack of 
significant difference in the HRs for infection-related versus infection-unrelated cancer 
(p=0.27). From our studies, activated inflammation is associated with an increased risk of 
both infection-related and infection-unrelated cancer [9]. Therefore, reduction of 
inflammation could have been a common mechanism by which cART may have reduced the 
risk of both types of cancer [38]. Third, we did not perform in situ hybridization analyses in 
cancer tissues; therefore, a definitive infectious origin could not be ascertained in cancer 
events classified as infection-related. Fourth, the number of cancer events was relatively 
small; this forced us to group heterogeneous malignancies into two categories and 
hampered our ability to quantify variation in risk of individual cancer types. We also had a 
hampered ability to fully explore potential mediators of the benefit of immediate cART and 
take our results as preliminary rather than definitive. A longer follow-up is needed in START 
to better understand the treatment differences and determine with accuracy which are the 
predictors for infection-related and infection-unrelated cancer. Nevertheless, few other 
randomised experiments are available to investigate the impact of cART on cancer risk. The 
Strategies for Management of Antiretroviral Therapy (SMART) study compared continuous 
cART use to CD4-guided structured cART interruptions [39]. As SMART participants who 
interrupted cART also had higher risk of cancer, in particular Kaposi sarcoma and non-
Hodgkin lymphoma [40], an individual participant data meta-analysis combining START and 
SMART may be useful for a better estimation of the impact of cART on the risk of specific 
cancer types. 
    To conclude, immediate cART initiation significantly reduces risk of cancer during HIV 
infection. Adjustment for latest HIV RNA level appeared to attenuate HRs of immediate 
versus deferred cART for infection-unrelated cancers more than infection-related cancers. 
The benefit of immediate cART doesn’t appear to be solely attributable to HIV RNA 
suppression and may also be mediated by other mechanisms, such as a curb on oncogenic 
virus coinfection and reduction of inflammation. Further research is needed to identify 
mediators of the benefit of immediate cART initiation in reducing cancer risk.  
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Tables1: START Types of malignancies by treatment group 
Table 2: START Baseline characteristics by cancer event status 
 
Figures 
Figure 1: Annual rates (95% CI) of any type cancer by year of follow up stratified by START 
arm. p-value for trend was 0.026 in the deferred cART arm and p for trend was 0.790 in the 
immediate cART arm.  
 
Figure 2: Kaplan-Meier curves giving the cumulative procentage of participants who 
developed infection-related cancer in each START arm.  
 
Figure 3: Kaplan-Meier curves giving the cumulative procentage of participants who 
developed infection-unrelated cancer in each START arm. 
 
Figure 4: Factors independently associated with infection-related and infection-unrelated 
cancer. Hepatitis B/C could not be estimated for infection-related cancer. 
 
Figure 5: Immediate versus deferred cART initiation and the risk of any type, infection-
related and infection-unrelated cancer in the START study. 
1 infection-related cancer: Human Herpesvirus 8 (Kaposi sarcoma), Epstein–Barr virus (non-
Hodgkin lymphoma, Hodgkin lymphoma), Human Papilloma virus (anal cancer, cervical 
cancer)   
2 infection-unrelated cancer: prostate cancer, lung cancer, testis cancer, plasma cell 
myeloma, fibrosarcoma, breast cancer, bladder cancer, ureteric cancer, malignant 
melanoma, myeloid leukemia, thyroid cancer, leiomyosarcoma, squamous cell carcinoma of 
the head and neck, squamous cell cancer, gastric adenocarcinoma, liver cancer 
A: univariable, estimated in a Cox proportional hazards model with a single treatment 
indicator 
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B: adjusted for baseline covariates: age, gender, race, geographical region, smoking, BMI, 
hepatitis B/C, baseline CD4 cell count and baseline log10 HIV RNA 
C: adjusted for latest CD4 cell count, modelled as a continuous variable 
D: adjusted for latest HIV RNA, modelled as <200 copies/mL vs HIV RNA >200 copies/mL 
E: adjusted for latest CD4 cell count and latest HIV RNA 
F: as in (B) with further adjustment for latest CD4 cell count and latest HIV RNA 
G: adjusted for latest log10 HIV RNA 
H: adjusted for latest CD4:CD8 ratio 
Table 1: START types of malignancies by treatment group 
 Immediate cART  Deferred cART  
Infection-related cancer   
Human herpes virus 8  
                       Kaposi sarcoma  
1 11 
Epstein-Barr virus         
       Non-Hodgkin lymphomas 
2 9 
                Hodgkin lymphomas 1 1 
Human papilloma virus   
                             Anal cancer 
1 2 
                       Cervical cancer 1 0 
Total 6 23 
   
Infection-unrelated cancer   
Prostate 2 3 
Lung 2 2 
Testicular 0 2 
Multiple myeloma 1 0 
Fibrosarcoma 1 0 
Breast 0 1 
Bladder 1 0 
Ureteral 0 1 
Malignant melanoma 0 1 
Myeloid leukemia 0 1 
Thyroid 0 1 
Leiomyosarcoma 0 1 
Squamous cell carcinoma of 
the skin 
1 0 
Squamous cell carcinoma of 
the head & neck 
0 1 
Gastric adenocarcinoma 0 1 
Liver  0 1 
Total 8 16 
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Table 2: START baseline characteristics by cancer event status 
 No Cancer Infection-related 
cancer 
Infection-unrelated 
cancer 
No participants 4632 29 24 
Demographics    
Age (years); median 
(IQR)  
36 (29, 44) 44 (31, 48) 51 (36, 59) 
Gender (% female)  26.9 10.3 25.0 
Race (%)    
Asian 8.4 0.0 4.2 
Black  30.3 13.8 16.7 
Latino/Hispanic  13.7 10.3 4.2 
White  44.2 75.9 75.0 
Other  3.5 0.0 0.0 
Region (%)    
High Income 45.8 51.7 79.2 
Low-Middle Income 54.2 48.3 20.8 
HIV History    
Likely mode of HIV 
infection (%) 
   
Sexual contact with 
person of same sex  
55.1 79.3 54.2 
Sexual contact with 
person of opposite sex  
38.3 20.7 37.5 
Injection drug use  1.4 0.0 4.2 
Blood 
products/other/unknown  
5.3 0.0 4.2 
Time participant known 
to be HIV+ (years); 
median (IQR)  
1.0 (0.4, 3.0) 0.7 (0.3, 3.4) 2.3 (0.6, 4.4) 
Laboratory Results    
CD4a (cells/mm3); 
median (IQR) 
651 (584, 764)  671 (587, 770) 638 (562, 759) 
CD4:CD8 ratio: median 
(IQR) 
0.66 (0.48, 0.90) 0.57 (0.42, 0.73) 0.56 (0.38, 0.75) 
CD8 (cells/mm3); 
median (IQR)  
1040 (774, 1400) 1152 (986, 1892) 1150 (821, 1499) 
HIV RNA 
(log10copies/mL); 
median (IQR)  
4.1 (3.5, 4.6) 4.6 (4.0, 5.0) 4.2 (3.9, 4.5) 
Highest HIV RNAb 
(log10copies/mL); 
median (IQR)  
4.3 (3.7, 4.8) 4.8 (4.1, 5.3) 4.5 (4.2, 5.0) 
Medical History    
Hepatitis B (%)  2.8 0.0 0.0 
Hepatitis C (%)  3.7 0.0 12.5 
Prior non-AIDS cancer 0.4 0.0 4.2 
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(%) 
Current smoker (%) 31.8 44.8 41.7 
Alcoholism or other 
substance dependence 
(%) 
3.3 0.0 4.2 
Body mass index 
(kg/m2); median (IQR) 
24.5 (22.1, 27.9) 25.9 (22.8, 29.6) 25.4 (22.3, 27.2) 
a
 Average of screening and baseline values 
b
 Documented in participant record 
